Chemo Free or Chemo First Navigating Lu-PSMA-617, Radium, and Treatment Sequencing

A regional roundtable discussion, moderated by Gregg Franklin, MD, PhD, New Mexico Cancer Center, explored current and emerging strategies in the management of metastatic castration-sensitive and castration-resistant prostate cancer, including clinical trial data, treatment sequencing, toxicity management, and the future role of targeted therapies and radiopharmaceuticals in patient care. Dr. Franklin was joined by other practitioners in the greater Albuquerque area, including Kathryn Chan, MD, Nexus Health; Laura Onorato, PA, New Mexico Cancer Center; Jose Avitia, MD, New Mexico Cancer Center; and Scott Herbert, MD, Nexus Health. In the fifth segment, the panel moves on to the use of radiopharmaceuticals, including Pluvicto, in metastatic castrate-resistant prostate cancer. They focus on how to sequence these therapies with chemotherapy, taking into account patient goals, disease characteristics, and long-term bone marrow preservation to maximize quality of life and future treatment options.